06May

Novo Nordisk's sales increased by 16% in Danish kroner and by 14% at constant ex ... Read more

28April

Novo Nordisk A/S – Reduction of the share capital ... Read more

04April

Rybelsus® (oral semaglutide) approved for the treatment of adults with type 2 di ... Read more

26March

Resolutions from the Annual General Meeting of Novo Nordisk A/S ... Read more

12May

Trading in Novo Nordisk shares by board members, executives and associated perso ... Read more

11May

Trading in Novo Nordisk shares by board members, executives and associated perso ... Read more

11May

Novo Nordisk A/S – Share repurchase programme ... Read more

11May

Novo Nordisk A/S purchases B shares worth DKK 3,051 million from Novo Holdings A ... Read more

01July

Silent period,

06August

Financial statement for the first six months of 2020,

01October

Silent period,

30October

Financial statement for the first nine months of 2020,

 

 

 

Investors

Share information
 

SHARE Magazine


Get the latest SHARE Magazine

上海快3- news for you as an investor

 

Corporate reporting

Capital markets day


Capital Markets Day 2019 
- Webcast and presentations

 

Private shareholders


Shareholder tools and systems for private investors

 

Investor materials

Contact Investor Relations

Sign-up: Company announcements


Sign up and receive our company announcements

 

Financial results and events overview

荣鼎彩开奖 极速快三 北京快3 安徽快3 诚信网投开户 上海快3 极速快3 上海11选5计划 河南快3 河北快3